XTNT Logo

Xtant Medical Holdings, Inc. (XTNT) 

AMEX
Market Cap
$57.09M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
770 of 774
Rank in Industry
98 of 99

Largest Insider Buys in Sector

XTNT Stock Price History Chart

XTNT Stock Performance

About Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler …

Insider Activity of Xtant Medical Holdings, Inc.

Over the last 12 months, insiders at Xtant Medical Holdings, Inc. have bought $0 and sold $0 worth of Xtant Medical Holdings, Inc. stock.

On average, over the past 5 years, insiders at Xtant Medical Holdings, Inc. have bought $568,485 and sold $50,444 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 41,670 shares for transaction amount of $49,837 was made by Brandt Kevin D (Chief Commercial Officer) on 2023‑11‑17.

List of Insider Buy and Sell Transactions, Xtant Medical Holdings, Inc.

2023-11-17PurchaseChief Commercial Officer
41,670
0.0341%
$1.20$49,837-25.73%
2023-01-18SaleChief Financial Officer
8,673
0.0082%
$0.61$5,283+55.93%
2022-10-19SalePresident and CEO
51,100
0.0471%
$0.62$31,820+9.68%
2022-10-18SalePresident and CEO
80,000
0.0763%
$0.68$54,008+4.62%
2022-10-07Purchasedirector
2.26M
1.4161%
$0.48$1.09M-4.23%
2022-08-15SaleChief Commercial Officer
18,700
0.0162%
$0.49$9,172+26.92%
2022-08-15SaleChief Financial Officer
1,270
0.0011%
$0.48$605+26.92%
2018-02-14Purchase
945,819
1.3083%
$7.20$6.81M+15.06%
2018-02-14Purchase
945,819
1.3083%
$7.20$6.81M+15.06%
2018-02-14Purchase
945,819
1.3083%
$7.20$6.81M+15.06%
2016-05-09PurchaseChief Executive Officer
5,000
0.0004%
$2.34$11,700-64.88%
2015-12-03Purchasedirector
2,300
0.0002%
$2.82$6,493-27.05%
2015-12-01Purchasedirector
1,000
<0.0001%
$2.85$2,850-28.07%
2015-11-20PurchaseEVP & Chief Scientific Officer
2,000
0.0002%
$2.99$5,983-28.23%
2015-11-20Purchasedirector
4,976
0.0004%
$3.00$14,928-28.23%
2015-11-19PurchaseEVP & Chief Scientific Officer
1,000
<0.0001%
$2.94$2,943-29.19%
2015-11-19Purchasedirector
24
<0.0001%
$2.90$70-29.19%
2015-11-18PurchaseEVP & Chief Scientific Officer
1,000
<0.0001%
$2.86$2,862-27.24%
2015-11-16PurchaseChief Executive Officer
3,000
0.0002%
$2.80$8,400-20.45%
2015-09-04PurchaseChief Executive Officer
81,522
0.0062%
$3.68$300,001-33.42%

Insider Historical Profitability

<0.0001%
ORBIMED ADVISORS LLC
5890884
4.2378%
$0.4110+15.06%
Rizzo Matthew
5890884
4.2378%
$0.4110+15.06%
Eggenberg Michael
5890884
4.2378%
$0.4110+15.06%
Vizirgianakis Stavros G.director
5850716
4.2089%
$0.4110<0.0001%
Kirschman David LouisEVP & Chief Scientific Officer
1701063
1.2237%
$0.4130<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
OrbiMed$85.54M56.1373.11M0%+$00.66
Altium Capital Management Lp$8.95M5.877.65M-4.73%-$444,272.381.05
Nantahala Capital Management Llc$4.68M3.074M0%+$00.22
The Vanguard Group$1.81M1.191.55M+3.22%+$56,533.23<0.0001
Renaissance Technologies$893,000.000.59763,310+3.02%+$26,205.87<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.